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Breast cancers (BC) carry a complex set of gene mutations that can influence their gene
expression and clinical behavior. We aimed to identify genes driven by the TP53 mutation
status and assess their clinical relevance in estrogen receptor (ER)-positive and ER-negative
BC, and their potential as targets for patients with TP53 mutated tumors. Separate ROC an-
alyses of each gene expression according to TP53mutation status were performed. The prog-
nostic value of genes with the highest AUC were assessed in a large dataset of untreated, and
neoadjuvant chemotherapy treated patients. The mitotic checkpoint gene MPS1 was the
most significant gene correlated with TP53 status, and themost significant prognostic marker
in all ER-positive BC datasets. MPS1 retained its prognostic value independently from the1; fax: þ39 0574 435176.
.it, libero.santarpia@humanitasresearch.it (L. Santarpia).
Therapeutics Unit, IRCCS e Humanitas Clinical and Research Center, Milan, Italy.
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Chemotherapytype of treatment administered. The biological functions of MPS1 were investigated in
different BC cell lines. We also assessed the effects of a potent small molecule inhibitor of
MPS1, SP600125, alone and in combination with chemotherapy. Consistent with the gene
expression profiling and siRNA assays, the inhibition of MPS1 by SP600125 led to a reduction
in cell viability and a significant increase in cell death, selectively in TP53-mutated BC cells.
Furthermore, the chemical inhibition of MPS1 sensitized BC cells to conventional chemo-
therapy, particularly taxanes. Our results collectively demonstrate that TP53-correlated ki-
nase MPS1, is a potential therapeutic target in BC patients with TP53 mutated tumors, and
that SP600125 warrant further development in future clinical trials.
ª 2014 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.1. Introduction our analysis, the human monopolar spindle 1 MPS1, in TP53-Breast cancer (BC) is a heterogeneous disease comprising
different molecular subtypes characterized by different types
of genetic alterations (Cancer Genome Atlas Network, 2012;
Santarpia et al., 2012; Sotiriou and Pusztai, 2009). Activation
of distinct gene and signaling pathways are associated with
prognosis and different responses to therapies (Iwamoto
et al., 2011; Santarpia et al., 2013). The tumor suppressor
TP53 is the most frequently altered gene in human cancer,
including BC. The importance of TP53 as a tumor suppressor
in BC is highlighted also by the occurrence of TP53 mutations
in the majority of HER2-positive, and basal-like BC subtypes,
and in an important percentage of luminal A and B subtypes
(Cancer Genome Atlas Network, 2012). TP53 mutations in BC
have been found associated with earlier onset, increased
aggressiveness of tumors, aneuploidy, lack of response to
endocrine therapies, and in general with poor prognosis
(Olivier et al., 2006). Few studies have analyzed a limited num-
ber of BC samples and identified prognostic gene signatures
correlated with TP53 status (Bonnefoi et al., 2011; Coutant
et al., 2011; Miller et al., 2005; Troester et al., 2006). TP53 is
an important regulator of several cellular signaling pathways
and the disruption of TP53 functions has been associated with
the impairment of DNA repair, cell cycle arrest and apoptosis,
which ultimately leads to genomic instability and cancer pro-
gression (Turner et al., 2013; Walerych et al., 2012).
Restoring endogenous TP53 function holds a lot of promise,
although it is still a challenging task due to the complex
signaling and multiple cellular functions of TP53. However,
considering the relevant role of TP53 signaling pathway in
BC, a potential targeting approach could be through the mod-
ulation of TP53-regulated downstream signals. This would be
particularly relevant to the tailoring of individual therapies,
especially when the treatment agents affect TP53-dependent
biological responses.
In this study, we integrated a large cohort of BC patients,
constructed a complete database to identify a more robust
gene signature of target genes associated with TP53mutation
status (Gyorffy et al., 2009). Several BC datasets for gene
expression data containing TP53 mutation status and clinical
informations of patients with long-term follow-up were
simultaneously analyzed. We combined different levels of
data to identify important genes potentially regulated by
mutant TP53 and having clinical relevance. Therefore, we
assessed the role of the most relevant gene that arose fromproficient and -deficient BC cell lines. Finally, we used a potent
inhibitor of MPS1, SP600125, alone and in combination with
chemotherapy, which resulted in reduced proliferation and a
significant cell death of BC cells. Moreover, inhibition of
MPS1 caused an important chemosensitization of cancer cells.2. Materials and methods
2.1. Datasets
We structured the collection of public datasets according to
the “Preferred Reporting Items for Systematic Reviews and
Meta-Analyses” (PRISMA) guidelines (Moher et al., 2009). The
complete workflow of the performed analyses is summarized
in Figure 1. We used a similar approach as previously reported
(Coutant et al., 2011) and in a very large cohort of BC patients.
To assess the prognostic value of the mutant TP53-related
genes, five independent BC datasets containing TP53mutation
status, gene expression and clinical data with follow-up were
used as the discovery cohort (estrogen receptor (ER)-
positive ¼ 511, and ER-negative ¼ 184) (Supplementary Table
1) (Bertheau et al., 2007; Desmedt et al., 2011; Iwamoto et al.,
2011; Miller et al., 2005; Reme et al., 2013).
To evaluate the association between mutant TP53-related
gene expressions and tumor relapse in BC patients, we tested
the expression of selected genes in patients who did not
receive any treatment by analyzing three different lymph
node negative BC datasets (Mainz GSE11121, Wang GSE2034,
and TRANSBIG GSE7390) for a total of 684 patients
(Supplementary Table 1).We also selected themost significant
gene that arose from our in silico analysis, a specific kinase
gene, MPS1 and assessed its prognostic role in BC patients
stratified for ER (after correction for HER2) who received
different chemotherapy regimens. Specifically, we analyzed
six independent cohorts of patients (n¼ 528)who receivedneo-
adjuvant chemotherapy (Supplementary Table 1) (Desmedt et
al., 2009; Hatzis et al., 2011; Karn et al., 2011).
2.2. Array processing
All arrays were downloaded and normalized in the R environ-
ment using the affy Bioconductor package as previously
described (Gyorffy and Schafer, 2009). For genes measured by
severalprobesets, themost reliableprobesetwasselectedusing
Figure 1 e General workflow of the study and data processing.
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sion value of 1000 in at least one of the samples were used in
the statistical computations. Additionally, all microarray files
were compared using the ranked expression of all genes to
spot microarrays re-published in different studies. The ER sta-
tus was identified as previously described (Gyorffy et al., 2012).
2.3. Statistical analysis
The ROC analysis was performed in the R statistical environ-
ment (http://www.r-project.org) using the ROC Bioconductor
library (http://www.bioconductor.org). A Bonferroni correc-
tionwas applied to account formultiple testing. The statistical
significance was set at p < 0.001.
The KaplaneMeier survival analysis was performed as pre-
viously described (Gyorffy et al., 2010). The KaplaneMeier sur-
vival plot and Cox regression models were computed in
WinStat 2013 (Robert K. Fitch Software, Germany). The func-
tional annotation and pathway analysis was performed using
the NCBI DAVID server (Huang et al., 2009a, 2009b) and the
Kyoto Encyclopedia of Genes and Genomes (KEGG) database
(Kanehisa and Goto, 2000).
Correlative studies between the most significant mutant
TP53-correlated genes and proliferation (MKI67 probe
[212021_s_at] expression) were performed on two indepen-
dent BC datasets (Miller et al., 2005; Iwamoto et al., 2011) by
Pearson correlation analysis.
2.4. Cell culture and treatments
ThehumanBCcell linesMCF7,MDA-MB-231 andT47Dwere ob-
tained from American Type Cell Collection (ATCC). MCF7 and
MDA-MB-231 cells were cultured in DMEM medium, and T47D
cells were cultured in RMPI-1640 medium supplemented with
10% fetal bovine serum and 1% penicillin/streptomycin. For
the experiments, the MCF7, MDA-MB-231 and T47D cells weregrown in phenol red-free culture medium under serum-free
conditions. 2H-Dibenzo[cd,g]indazol-6-one (SP600125) was
selectedasaMPS1 inhibitor fromVichem’sChemicalValidation
Library (BennettBrydonL. et al.,USPAt.App.Publ., 20040072888,
15 Apr. 2004). SP600125 was synthesized in a one-step cycliza-
tion of 1-chloro-anthraquinonewith hydrazine hydrate, as pre-
viously described (Kim and Wiemer, 2004). SP600125 was
solubilized in DMSO and was used at a final concentration of
10 mM; paclitaxel and doxorubicin were used at concentration
of 1 mM and 4 mM, respectively. The appropriate amount of
DMSOwas employed for the negative control condition.
2.5. Western blotting
The cells were harvested and lysed in a RIPA buffer containing
protease inhibitors (SigmaeAldrich). The total protein (30 mg)
was denatured, separated by 4%e20% SDS-PAGE (BioRad)
and transferred to Immuno-BlotTM polyvinylidene difluoride
(PVDF) membranes (BioRad). After blocking the membranes
in 5% non-fat milk powder dissolved in phosphate-buffered
saline (PBS), they were incubated overnight in 0.5% non-fat
milk powder at 4 C with primary anti-MPS1 antibody (Milli-
pore). Afterwards, the membranes were incubated for one
hourwith anHRP-conjugated anti-mouse IgG (Millipore). After
washing, a chemiluminescent substrate (Millipore) was added
to themembranes, which were then exposed in the Chemidoc
XRS station (Biorad). To control for protein loading, mem-
branes were stripped and reprobed with an anti-b actin anti-
body (Life Technologies). Band intensities were analyzed and
calculated using the Quantity One 4.6 software (BioRad).
2.6. Cell viability and proliferation assays
Viable cells were identified using the 3-[4,5-dimethylthiazol-2-
yl]-2,5-diphenyltetrazolium bromide assay (MTT; Sigma).
Briefly, cells were plated (3  103 cells/well) on 96-well plates
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SP600125 or DMSO (for control cells) was added 24 h later.
Seventy-two hours after the SP600125 treatment, the MTT re-
agent (5 mg/ml in PBS) was added to each well, followed by in-
cubation for 4 h at 37 C. The MTT crystals in each well were
solubilized in DMSO. The absorbance was read at 560 nm
with an iMark plate reader (BioRad). All the treatments were
performed in triplicate, and cell viability was expressed as a
percentage of the untreated controls (mean  S.D.). For
proliferation assay, serum starved BC cell lines
(approximately 80% density) were treated with SP600125 or
DMSO. Cell proliferation was assessed using a commercial
kit (cell proliferation enzyme-linked immunosorbent assay,
5-bromo-20-deoxyuridine (BrdU); Roche Applied Science) ac-
cording to the manufacturer’s instructions. Briefly, after 48 h
of incubation with SP600125 or DMSO, the cells were labeled
with BrdU for 3 h at 37 C. The cells were fixed and incubated
with peroxidase-conjugated anti-BrdU antibody. Then, the
peroxidase substrate 3,30,5,50-tetramethylbenzidine was
added, and BrdU incorporation was quantitated by the differ-
ence in the absorbance at 370 and 492 nm.2.7. Assessment of apoptosis by Annexin V/propidium
iodide double-staining assay
Cells were incubated for 48 h with SP600125 and then
collected, washed with PBS, and resuspended in Annexin V
binding buffer (1  106 cells/ml final concentration). The
amount of apoptotic cells were identified by double supravital
staining with recombinant fluorescein isothiocyanate-
conjugated Annexin V antibody (Dako) and propidium iodide.
Flow cytometric analysis was performed immediately after
the supravital staining. The data acquisition and analysis
were performed in a FACSCalibur flow cytometer using Cell-
Quest software (BD Biosciences).Table 1eReceiver Operating Characteristic analysis in ER-positive
and ER-negative breast cancer patients. *p< 0.001.MPS1 was the
gene with the highest AUC value in ER-positive tumors.
Affymetrix ID Gene symbol AUC p-value
ER-positive
204822_at MPS1 0.814 <1E-16*
202870_s_at CDC20 0.804 <1E-16*
210052_s_at TPX2 0.803 <1E-16*
204962_s_at CENPA 0.802 <1E-16*
202705_at CCNB2 0.790 <1E-16*
201710_at MYBL2 0.789 <1E-16*
208079_s_at AURKA 0.785 <1E-16*
203438_at STC2 0.782 <1E-16*
209773_s_at RRM2 0.781 <1E-16*
ER-negative
201774_s_at NCAPD2 0.779 1.29E-12*
209710_at GATA2 0.759 2.01E-10*
201286_at SDC1 0.729 4.96E-09*
203233_at IL4R 0.765 1.15E-08*
203758_at CTSO 0.759 1.28E-08*
209421_at MSH2 0.733 5.90E-08*
219076_s_at PXMP2 0.739 6.48E-08*
208763_s_at TSC22D3 0.741 8.01E-08*
211623_s_at FBL 0.759 9.26E-08*2.8. siRNA transfections
MPS1was targeted with two distinct siRNAs (Dharmacon Inc.)
thatwere delivered intoMCF7,MDA-MB-231 and T47D BC cells
by oligofectamine (Invitrogen). After 48 h, the effect of
silencing on protein expression levels was determined by
immunoblotting. We optimized the transfection conditions
for each cell lines, as previously described, with minimum
modifications (Bianchini et al., 2010). Briefly, we used three
different types of negative controls, including cells grown in
regular OptiMEM medium (Invitrogen), cells grown in the
presence of transfection reagents only, and cells transfected
with control siRNA, including four different constructs and
four different siRNA constructs (Dharmacon Inc.). Different
positive controls (40 nmol/L final concentration) were used
to define the optimal transfection efficiency conditions.
Gene silencing was performed in three replicates in 96-well
plates using predetermined optimal transfection conditions.
The cells were seeded at a density that yielded 70e80% conflu-
ence in the control wells at 96 h. Each plate included wells
with target siRNAs (40 nmol/L per well in a 50 mL total volume)
and negative and positive siRNA controls; the plates were
incubated at 37 C for 96 h.2.9. Immunoprecipitation/kinase assay
The immunoprecipitation/kinase assay was performed as
previously described (Huang et al., 2009a,b). Briefly, MCF7,
MDA-MB-231 and T47D cells were lysed, and MPS1 was
immunoprecipitated from the cell lysates with anti-MPS1
antibody (Acris Antibodies GmbH) and washed three times
in CSK Buffer (10 mM piperazine-N,N-bis(2-ethanesulfonic
acid) (pH 7.0), 100 mM NaCl, 3 mM MgCl2, 300 mM sucrose,
and 0.1% NP-40) to which 0.7 M LiCl was added for the sec-
ond wash. After two washes in kinase buffer, the kinase re-
action was carried out using His-TP53 as substrate. The
reaction was stopped by the addition of a 0.5 volume of pro-
tein sample buffer, and the proteins were resolved by SDS-
PAGE. The phosphorylation of TP53 was visualized by West-
ern blotting using an anti-phospho-TP53 antibody (Cell
Signaling).3. Results
3.1. Identification of genes correlated with TP53 status
Five independent BC datasets containing informations on
TP53 mutation status, gene expression and clinical data
were used as the discovery cohort (Supplementary Table
1). We independently assessed ER-positive (n ¼ 511) and
ER-negative (n ¼ 184) patients to identify genes associated
with mutant TP53 using ROC analysis. We identified 4172
and 794 mutant TP53-associated genes in ER-positive and
ER-negative groups, respectively ( p < 0.001; Supplementary
Table 2A and B). The ROC results for the top ranking genes
for ER-positive and ER-negative BC patients are listed in
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MPS1 kinase, was the most significant one associated with
TP53 status (AUC ¼ 0.814, p < 1E-16). MPS1 remained signif-
icantly associated with TP53 status even when the individ-
ual datasets were analyzed separately (GSE3494:
AUC ¼ 0.852, p < 1E-16; GSE22093: AUC ¼ 0.78, p ¼ 1.45E-
06; E-MTAB-43: AUC ¼ 0.82, p ¼ 9.0E-04; E-MTAB-365:
AUC ¼ 0.77, p ¼ 7.42E-14). To evaluate the impact of the
most significant genes associated with TP53 status we used
the DAVID server. We identified specific and significantly
enriched canonical signaling pathways potentially activated
by mutations of TP53 ( p < 0.01) (Supplementary Table 3).
Functional annotation clustering for all the significantlyFigure 2 e Survival analysis in neoadjuvant chemotherapy-treated breast ca
analysis. (n.s. [ not significant; RFS [ relapse-free survival).mutant TP53-associated genes in ER-positive tumors
revealed “Cell cycle” ( p ¼ 9.2E-6), “DNA replication”
( p ¼ 1.0E-3), “Mismatch repair” ( p ¼ 1.9E-3), “TP53 signaling
pathway” ( p ¼ 2.8E-3) and “Nucleotide excision repair”
( p ¼ 1.3E-2). The most relevant enriched pathways among
the mutant TP53-correlated genes in the ER-negative pa-
tients were “Mismatch repair” ( p ¼ 1.1E-6), “DNA replica-
tion” ( p ¼ 1.2E-6), “Cell cycle” ( p ¼ 1.4E-6), “Pathways in
cancer” ( p ¼ 6.0E-3), “Nucleotide excision repair”
( p ¼ 7.0E-3) and “ECM-receptor interaction” ( p ¼ 1.1E-2).
Of note, cell cycle was the category hit by most of the genes;
therefore, we used the KEGG cell cycle pathway map to visu-
alize the genes with altered expression in TP53 mutantncer patients for three of the top ranking genes identified using ROC
Table 2 e Cox regression analyses in ER-positive and ER-negative
breast cancer patients performed on the genes ranked by the highest
AUC values. *p< 0.001. MPS1 was the most significant gene
associated with poor outcome in ER-positive tumors.
Affymetrix ID Gene symbol HR p-value
ER-positive
204822_at MPS1 2.5 4.0E-05*
202870_s_at CDC20 2.1 1.2E-03
210052_s_at TPX2 1.47 0.08
204962_s_at CENPA 2.1 1.3E-03
202705_at CCNB2 2.2 3.7E-04*
201710_at MYBL2 1.31 0.22
208079_s_at AURKA 2.2 3.9E-04*
203438_at STC2 0.32 7.0E-07*
209773_s_at RRM2 2.3 2.9E-04*
ER-negative
201774_s_at NCAPD2 1.14 0.56
209710_at GATA2 1.30 0.23
201286_at SDC1 1.02 0.94
203233_at IL4R 1.20 0.41
203758_at CTSO 0.73 0.16
209421_at MSH2 0.82 0.36
219076_s_at PXMP2 0.86 0.5
208763_s_at TSC22D3 0.84 0.43
211623_s_at FBL 0.88 0.54
Figure 3 e MPS1 activity and the effect of SP600125 (MPS1i) in
breast cancer cell lines. Immunoprecipitated endogenous MPS1
phosphorylated TP53 on Thr18. Immunoprecipitation/kinase assays
were performed using MPS1 immunoprecipitated from MCF7, T47D
and MDA-MB-231 cells. Normal rabbit immunoglobulin G was used
as control. Phosphorylation of the substrate (His-TP53) was detected
by Western blotting using an anti-phospho-Thr18-TP53 antibody.
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more frequent in ER-negative tumors (Chi-square test
p ¼ 0.0001).
3.2. Survival analysis in untreated breast cancer
patients and patients treated with systemic chemotherapy
To evaluate the prognostic value of the genes associated with
TP53 status we downloaded the expression data for 684 lymph
node negative untreated patients including 553 ER-positive
and 132 ER-negative patients of three independent datasets
(Supplementary Table 1). In the ER-positive patients, low
MPS1 expression was associated with longer relapse-free sur-
vival (HR ¼ 1.89, p ¼ 1.85E-05, Supplementary Figure 2). In the
untreated BC series, after correction for HER2 (Cox multivar-
iate regression model), MPS1 was still significant prognostic
(HR ¼ 1.87, p ¼ 3.99E-05). MPS1 retained its prognostic signifi-
cance even after stratification for lymph node status (lymph
node positive patients: HR¼ 2.4, p = 4.9E-04; lymph node nega-
tive patients: HR ¼ 11.9, p = 0.0022).
We also assessed the association of these classes of genes
with clinical outcome in patients treated with systemic ther-
apy. Survival data available for 528 BC patients who received
neoadjuvant chemotherapy (Supplementary Table 1) were
used for further validation by employing KaplaneMeier anal-
ysis (Figure 1). None of these validation samples was included
in the discovery cohort. The KaplaneMeier plots for three of
the top genes in each cohort are depicted in Figure 2. We per-
formedCox regression analysis in ER-positive and ER-negative
BC patients on the genes with the highest AUC values (Table
2). We found that the gene with the highest AUC value in
ER-positive tumors, MPS1, was also strongly associated with
patient relapse-free survival (HR ¼ 2.5, p ¼ 4.0E-05; Table 2).
Analysis in ER-negative tumors did not reveal any gene corre-
lated with TP53 status significantly associated with risk of
relapse (Table 2 and Figure 2). In addition, to demonstrate
the robustness of the median approach used in our study we
randomly divided the neoadjuvant treated ER-positive cohort
into two cohorts of equal size. Themedian expression ofMPS1
in the training cohort was used in the Cox regression analysis
for both the training and the testing cohorts; the gene retained
its significant association with relapse-free survival in both
cohorts (Supplementary Figure 3). Pearson correlation anal-
ysis demonstrated that almost all of the top TP53-associated
genes were correlated with proliferation (Supplementary
Table 4).
3.3. Loss of MPS1 results in decreased survival and
induction of apoptosis in breast cancer cells
We analyzed a large BC cell line dataset (http://www.ebi.ac.uk/
arrayexpress/, accession No. E-TABM-157) (Neve et al., 2006)
and verified that MPS1 was expressed, though at different
levels, in all BC cell lines (data not shown). For in vitro analysis,
weselectedoneTP53wild-typecell line (MCF7, luminal)andtwo
TP53-mutated BC cell lines (T47D, luminal and MDA-MB-231,
basal-like). To determine the basal MPS1 activity levels and
the effect of theMPS1 inhibitor SP600125 on BC cells, in vitro ki-
nase assays were employed using MPS1 immunoprecipitated
fromMCF7, T47D and MDA-MB-231 cells. The phosphorylationof TP53, a downstream target of MPS1, at threonine-18 was
assessedbyWesternblotting. As shown in Figure 3,MPS1 activ-
ity was detected in all BC cell lines and was found to be consis-
tently elevated in T47D cells. Furthermore, SP600125 at 10 mM
significantly reduced the MPS1 activity in all BC cells
(Figure 3), confirming MPS1 as a specific target of SP600125.
Reduction in MPS1 levels has been found to decrease the
viability of several human cancer cell lines (Janssen et al.,
2009). To explore the role of MPS1 in BC cells, we examined
the effect of MPS1 gene silencing in MCF7, MDA-MB-231 and
T47D cell lines. Treatment with MPS1-siRNA resulted in a
reduced expression of the MPS1 protein in all of the cell lines
tested (Figure 4A), whereas control cells and non-targeting
siRNA transfected cells retained normal MPS1 protein
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ciency of theMPS1-siRNA. The cell viability and cell prolifera-
tionwere then assessed by theMTT assay (Figure 4B) and BrdU
incorporation (Figure 4C), respectively. We found that MPS1
silencing had no effect on the proliferative potential of MCF7
and a slight effect ( p < 0.05) on cell viability and proliferation
in both of the TP53-mutant cell lines. This result indicates that
the TP53-mutated BC cells and TP53wild-typeMCF7 cells have
differential requirements forMPS1, potentially corresponding
to their TP53 functional status.
Similar results were obtained with the MPS1 inhibitor
SP600125 (Figure 5A). Inhibition of MPS1 was not sufficient to
consistently reduce the viability of MCF7 cells and showed
only marginal effects ( p < 0.05) on the viability of the TP53-
mutated BC cell lines (Figure 5A). In the presence of the
MPS1 inhibitor, the TP53wild-typeMCF7 cells did notmanifest
any increased staining for Annexin V (Figure 5B). Conversely,
both TP53-mutated BC cell lines showed amarkedly increased
rate of apoptosis (Figure 5B), consistent with the concept that
a reduction inMPS1 causes cellular apoptosis rather than sim-
ply a reduction in cell growth rates. Furthermore, MPS1Figure 4 e Viability and proliferation of breast cancer cells after the reduct
showing protein levels of parental control (transfection reagents only), non
48 h. Cell viability (B) and cell proliferation (C) after silencing of MPS1 w
Error bars represent the S.D. of triplicate measurements. #p< 0.05.inhibitionwasmore efficient ( p< 0.01) in increasing apoptosis
in ER-positive T47D cells compared with ER-negative MDA-
MB-231 cells ( p < 0.05). These results, in line with the in silico
analyses, establish that MPS1 inhibition preferentially
impaired TP53-mutated cells, and that MPS1 is a potential
therapeutic target for TP53-mutated ER-positive breast
cancers.
To further assess the potential therapeutic value of MPS1
inhibition in combined therapy, we analyzed the effect of
SP600125 in combination with conventional chemothera-
peutic drugs in different BC cell lines (Figure 6). SP600125 alone
consistently reduced TP53-mutated cells survival ( p < 0.05),
but had no significant effects on MCF7 survival (Figure 6). Of
note, MPS1 inhibition had a synergistic effect on cell survival
in mutant TP53 cells either in combination with doxorubicin
( p < 0.01), or with paclitaxel ( p < 0.001). Although the combi-
nation with taxanes and anthracyclines caused a decrease of
cell survival also in MCF7 ( p < 0.05), the observed synergistic
effect was negligible with respect to TP53-mutated cells, sug-
gesting that this type of cells is sensitive at less extent to the
inhibition of MPS1 (Figure 6).ion of MPS1 expression levels with siRNA. (A) Western blot analysis
-targeting construct-transfected, and MPS1 siRNA-transfected after
ere determined by MTT assay and BrdU incorporation, respectively.
Figure 5 e Effects of SP600125 (MSP1i) on viability and apoptosis in breast cancer cell lines. MCF7, T47D and MDA-MB-231 cells were treated
with 10 mM SP600125 or DMSO alone (control) for 72 h. (A) Cell viability was analyzed by MTT assay. (B) Apoptotic cells were detected by
propidium iodide and Annexin V staining. Histogram comparing the percent of apoptotic cells in each of the different treatments are shown. Error
bars represent the S.D. of triplicate measurements. #p< 0.05, *p< 0.01.
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TP53 is an important prognostic indicator in BC, and dysfunc-
tions of this gene have been demonstrated to affect different
gene patterns. Moreover, BC with TP53 mutations tend to
have fewermutations in other driver cancer genes, suggestingFigure 6 e Effects of SP600125 (SP) in combination with taxane (tax) or ant
MCF7, T47D and MDA-MB-231 cells were treated with 10 mM SP alone o
bars indicate the S.D. (n [ 3). #p< 0.05, *p< 0.01, **p< 0.001.a crucial role of the TP53 signaling pathway in these cancer
cells (Cancer Genome Atlas Network, 2012).
In this study, we assembled several different BC datasets to
assess the effect of TP53 status on the potential regulation of
specific genes, to evaluate their prognostic value, and identify
genes to target in TP53 mutated ER-positive and ER-negative
BC subtypes. We established two distinct sets of geneshracycline (dox) on breast cancer cells survival assessed by MTT assay.
r in combination with paclitaxel (1 mM) or doxorubicin (4 mM). Error
M O L E C U L A R O N C O L O G Y 8 ( 2 0 1 4 ) 5 0 8e5 1 9516associated with TP53 status in ER-positive and ER-negative
BCs and demonstrated that single genes were able to predict
TP53 dysfunction in both subtypes. This suggests a potential
intersection in the activation of transcriptional programs
regulated by TP53 in both cancer groups. However, genes
correlated with mutant TP53 were associated with relapse-
free survival only in ER-positive tumors, suggesting that the
expression of some genes in TP53 mutated tumors may be
dependent on ER status. The prognostic genes associated
with TP53 status and identified in the discovery dataset were
confirmed in a large cohort of lymph-node negative untreated
BC patients.
Theprognostic valueof the two sets of geneswas confirmed
in ER-positive and ER-negative BCpatients treatedwithneoad-
juvant chemotherapies, including taxane-anthracycline based
regimens. The genes associated with TP53 status were
confirmed to be prognostic only in ER-positive tumors and
independently from the type of chemotherapy received. The
same analysis performed for TP53-genes on the ER-negative
group had no consistent prognostic value. Some of the genes
associatedwithTP53 statusarealso linked to cell cycleandpro-
liferation, making the latter a potential confounding variable
in the identification of prognostic biomarker. However, impor-
tant studies have demonstrated that despite TP53 mutations
are directly linked to high tumor proliferation rates, both fac-
tors remain independently associated with BC prognosis
(Allred et al., 1993; Yerushalmi et al., 2010). In our results, as ex-
pected, we found that numerous top-ranked genes linked to
TP53 status were also significantly associated with prolifera-
tion and tumor relapse. To make our approach reliable and
robust, from our data we selected MPS1 (also named TTK ),
the gene with the highest AUC value linked with TP53 status,
and most significantly associated with poor prognosis. MPS1
was previously included in different prognostic proliferation-
based signatures (Sotiriou et al., 2006; Bianchini et al., 2010),
and in a 16-kinase signature that was able to further distin-
guish two subgroups of luminal A tumors with different sur-
vival (Finetti et al., 2008). In spite of the strong link between
MPS1 and proliferation, this kinase has also recently been
established aspart of a genemoduledependent onTP53 status,
which further stratified luminal tumors, independently of pro-
liferation. These observations shed light on the biological con-
sequences of specific defective cell cycle checkpoints upon
regulation of TP53-modulated kinase genes, such as MPS1, in
this subgroupof luminal tumors,whicharemost likely charac-
terized by higher genomic instability (Fredlund et al., 2012).
These findings indirectly support the correctness of the
approach and gene selection adopted in our study, and suggest
that this poor prognosis luminal subgroup could be enriched
for distinct genomically unstable TP53-mutated tumors.
These observations also suggest that TP53 mutations may
activate specific transcriptional checkpoint programs that in
turn could destabilize the interactions between TP53 and ER
thus explaining the resistance of specific ER-positive tumors
to apoptosis (Bailey et al., 2012). Accordingly, in our study,
the top-scored genes associated with TP53 status in ER-
positive tumors were enriched for functions related to mitotic
spindle assembly and checkpoint regulation (MPS1, CDC20,
TPX2, CCNB2, and AURKA). Our data are also in agreement
with a recent study demonstrating that a subset of poorprognostic luminal tumors was linked to TP53-regulated pro-
grams, and genomic instability (Ciriello et al., 2013).
TP53 is capable to regulate a number of checkpoint and
mitotic kinases; few of these have been recently investigated
as potential targets for therapies (Ha and Breuer, 2012). The
MPS1 gene encodes for a dual serine/threonine kinase, which
is involved in the mitotic spindle assembly checkpoint (SAC)
(Jones et al., 2005; Weiss and Winey, 1996), chromosome sta-
bility (Leng et al., 2006), DNA damage checkpoints (Wei et al.,
2005) and the TP53-dependent mitotic checkpoint (Huang
et al., 2009c). In this study, the prognostic value of MPS1 in
BC was confirmed in both ER-positive untreated patients,
and in ER-positive patients treated with neoadjuvant chemo-
therapy. MPS1 was prognostic after stratification for lymph
node status, and as TP53 status, independently from the
type of therapy administrated (Bonnefoi et al., 2011). Our
in vitro results paralleled and supported the in silico data, sug-
gesting that MPS1 is a potential TP53-regulated kinase to
target in BC. Accordingly, in our study, the inhibition of
MPS1 by siRNA and a chemical inhibitor, strengthened the
important role played by this kinase in a subset of TP53-
mutated ER-positive tumors characterized by poor prognosis.
We demonstrated that all BC cell lines expressed MPS1 and
that the loss of MPS1 resulted in decreased cell viability and
proliferation. The TP53-mutated (MDA-MB-231 and T47D)
and TP53 wild-type (MCF7) BC cells had differential require-
ments for MPS1, potentially corresponding to their different
TP53 functional status. The potent biological activity of
SP600125, a small pan-kinase mitotic inhibitor, demonstrated
that the inhibition of MPS1 resulted in decreased cell viability
and induction of apoptosis in BC cell lines with dysfunctions
of TP53. MPS1, regulates checkpoint activity that is selectively
required to sustain the proliferation of aneuploid tumors, and
it is associated with chromosomal instability in different can-
cer types (Carter et al., 2006; Daniel et al., 2011). Our data sug-
gest that the checkpoint inactivation leading to aneuploidy
may serve as a mechanism by which MPS1 inhibition causes
the loss of cell viability and the induction of apoptosis in
mutated BC cells. In line with our findings, MPS1 has recently
been suggested as a potential target for tumors characterized
by high genomic instability, such as melanomas mutated for
BRAF-V600E (Liu et al., 2013), basal-like BC (Maire et al.,
2013), and glioblastomas (Tannous et al., 2013).
In this study, we confirmed a significant high activity of
SP600125 in TP53 mutated BC cell lines, which are known to
be characterized by high genomic instability and aneuploidy.
Additional studies using these classes of anti-checkpoint/
mitotic inhibitors in these types of cancer cells support the
consistency of our findings (Colombo et al., 2010).
Our data also proved that SP600125 added to cytotoxic
drugs has an important effect on cell survival, enhancing
the sensitivity of BC cells to chemotherapy, particularly to
anti-tubulin drugs. Comparable results were reported on
recent different studies, which showed that MPS1 depletion
was highly toxic in cancer cell lines if added in combination
with chemotherapy (Janssen et al., 2009; Jemaa et al., 2013).
TP53-incompetent cells can override mitotic checkpoints
becoming aneuploid, and contributing to chromosomal insta-
bility and resistance to therapy (Weaver and Cleveland, 2005;
Cheok et al., 2011; Murray et al., 2012).
MO L E C U L A R O N C O L O G Y 8 ( 2 0 1 4 ) 5 0 8e5 1 9 517Consequently, it will be important to select compounds
that preferentially kill TP53-incompetent cells (Brown et al.,
2009). Accordingly, SP600125 could selectively target TP53-
mutated proliferating mitotic cells in tumors, enhancing cell
sensitivity to current chemotherapeutic drugs. Moreover,
SP600125 may exert these cytotoxic effects through the con-
current inhibition of few serine/threonine kinases; although,
the inhibition of MPS1 appears to be co-responsible for the
preferential effects of SP600125 on the cell cycle of TP53/
cells (Jemaa et al., 2012; Brown et al., 2009). Accordingly, we
have demonstrated that SP600125 kills TP53-defective cells
more efficiently than their TP53-proficient counterparts
in vitro. Our data also suggest that mitotic associated check-
point drugs including, SP600125 (or other drugs with “similar”
activity, such as, NMS-P715, MPI-0479605, AZ3146 etc.), could
be suitable candidates for further development toward clinical
studies in genomically unstable breast tumors.
In conclusion, altogether our data demonstrate that TP53
status is associated with important key mitiotic-checkpoint
kinases, such as MPS1, involved in tumor relapse in a specific
subset of ER-positive tumors. MPS1 is predominantly
expressed and activated by the loss of function mutations of
TP53 in human breast tumors, and the inhibition of this
marker efficiently increases the apoptosis of TP53 defective
BC cell lines, particularly those expressing the estrogen recep-
tor. Finally, the concurrent inhibition of important kinases,
including MPS1, by SP600125 could have a synergistic cellular
proapoptotic effect, which may be exploited for the therapeu-
tic advantage of increasing cancer cell toxicities.
Acknowledgements
This study was supported by the OTKA PD 83154 Grant (to
B.G.), the Predict project (Grant no. 259303 of the EU
Health.2010.2.4.1.-8 call to B.G.), Associazione Italiana per la
Ricerca sul Cancro (AIRC Grant-6251 to L.S.).Appendix A.
Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.molonc.2013.12.018R E F E R E N C E S
Allred, D.C., Clark, G.M., Elledge, R., Fuqua, S.A., Brown, R.W.,
Chamness, G.C., Osborne, C.K., McGuire, W.L., 1993.
Association of p53 protein expression with tumor cell
proliferation rate and clinical outcome in node-negative
breast cancer. J. Natl. Cancer Inst. 85, 200e206.
Bailey, S.T., Shin, H., Westerling, T., Liu, X.S., Brown, M., 2012.
Estrogen receptor prevents p53-dependent apoptosis in breast
cancer. Proc. Natl. Acad. Sci. U S A 109, 18060e18065.
Bertheau, P., Turpin, E., Rickman, D.S., Espie, M., de Reynies, A.,
Feugeas, J.P., Plassa, L.F., Soliman, H., Varna, M., de
Roquancourt, A., Lehmann-Che, J., Beuzard, Y., Marty, M.,
Misset, J.L., Janin, A., de The, H., 2007. Exquisite sensitivity ofTP53 mutant and basal breast cancers to a dose-dense
epirubicin-cyclophosphamide regimen. PLoS. Med. 4, e90.
Bianchini, G., Iwamoto, T.,Qi, Y., Coutant, C., Shiang, C.Y.,Wang, B.,
Santarpia, L., Valero, V., Hortobagyi, G.N., Symmans, W.F.,
Gianni, L., Pusztai, L., 2010. Prognostic and therapeutic
implications of distinct kinase expression patterns in different
subtypes of breast cancer. Cancer Res. 70, 8852e8862.
Bonnefoi, H., Piccart, M., Bogaerts, J., Mauriac, L., Fumoleau, P.,
Brain, E., Petit, T., Rouanet, P., Jassem, J., Blot, E., Zaman, K.,
Cufer, T., Lortholary, A., Lidbrink, E., Andre, S., Litiere, S.,
Lago, L.D., Becette, V., Cameron, D.A., Bergh, J., Iggo, R.EORTC
10994/BIG 1-00 Study Investigators, 2011. TP53 status for
prediction of sensitivity to taxane versus non-taxane
neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG
1-00): a randomised phase 3 trial. Lancet Oncol. 12, 527e539.
Brown, C.J., Lain, S., Verma, C.S., Fersht, A.R., Lane, D.P., 2009.
Awakening guardian angels: drugging the p53 pathway. Nat.
Rev. Cancer 9, 862e873.
Cancer Genome Atlas Network, 2012. Comprehensive molecular
portraits of human breast tumors. Nature 490, 61e70.
Carter, S.L., Eklund, A.C., Kohane, I.S., Harris, L.N., Szallasi, Z.,
2006. A signature of chromosomal instability inferred from
gene expression profiles predicts clinical outcome in multiple
human cancers. Nat. Genet. 38, 104e1048.
Cheok, C.F., Verma, C.S., Baselga, J., Lane, D.P., 2011. Translating
p53 into the clinic. Nat. Rev. Clin. Oncol. 8, 25e37.
Ciriello, G., Sinha, R., Hoadley, K.A., Jacobsen, A.S., Reva, B.,
Perou, C.M., Sander, C., Schultz, N., 2013. The molecular
diversity of Luminal A breast tumors. Breast Cancer Res. Treat
141, 409e420.
Colombo, R., Caldarelli, M., Mennecozzi, M., Giorgini, M.L.,
Sola, F., Cappella, P., Perrera, C., Depaolini, S.R., Rusconi, L.,
Cucchi, U., Avanzi, N., Bertrand, J.A., Bossi, R.T., Pesenti, E.,
Galvani, A., Isacchi, A., Colotta, F., Donati, D., Moll, J., 2010.
Targeting the mitotic checkpoint for cancer therapy with
NMS-P715, an inhibitor of MPS1 kinase. Cancer Res. 70,
10255e10264.
Coutant, C., Rouzier, R., Qi, Y., Lehmann-Che, J., Bianchini, G.,
Iwamoto, T., Hortobagyi, G.N., Symmans, W.F., Uzan, S.,
Andre, F., de The, H., Pusztai, L., 2011. Distinct p53 gene
signatures are needed to predict prognosis and response to
chemotherapy in ER-positive and ER-negative breast cancers.
Clin. Cancer Res. 17, 2591e2601.
Daniel, J., Coulter, J., Woo, J.H., Wilsbach, K., Gabrielson, E., 2011.
High levels of the Mps1 checkpoint protein are protective of
aneuploidy in breast cancer cells. Proc. Natl. Acad. Sci. U S A
108, 5384e5389.
Desmedt, C., Giobbie-Hurder, A., Neven, P., Paridaens, R.,
Christiaens, M.R., Smeets, A., Lallemand, F., Haibe-Kains, B.,
Viale, G., Gelber, R.D., Piccart, M., Sotiriou, C., 2009. The gene
expression grade Index: a potential predictor of relapse for
endocrine-treated breast cancer patients in the BIG 1-98 trial.
BMC. Med. Genomics 2, 40.
Desmedt, C., Di Leo, A., de Azambuja, E., Larsimont, D., Haibe-
Kains, B., Selleslags, J., Delaloge, S., Duhem, C., Kains, J.P.,
Carly, B., Maerevoet, M., Vindevoghel, A., Rouas, G.,
Lallemand, F., Durbecq, V., Cardoso, F., Salgado, R., Rovere, R.,
Bontempi, G., Michiels, S., Buyse, M., Nogaret, J.M., Qi, Y.,
Symmans, F., Pusztai, L., D’Hondt, V., Piccart-Gebhart, M.,
Sotiriou, C., 2011. Multifactorial approach to predicting
resistance to anthracyclines. J. Clin. Oncol. 29, 1578e1586.
Finetti, P., Cervera, N., Charafe-Jauffret, E., Chabannon, C.,
Charpin, C., Chaffanet, M., Jacquemier, J., Viens, P.,
Birnbaum, D., Bertucci, F., 2008. Sixteen-kinase gene
expression identifies luminal breast cancers with poor
prognosis. Cancer Res. 68, 767e776.
Fredlund, E., Staaf, J., Rantala, J.K., Kallioniemi, O., Borg, A.,
Ringner, M., 2012. The gene expression landscape of breast
M O L E C U L A R O N C O L O G Y 8 ( 2 0 1 4 ) 5 0 8e5 1 9518cancer is shaped by tumor protein p53 status and epithelial-
mesenchymal transition. Breast Cancer Res. 14, R113.
Gyorffy, B., Benke, Z., Lanczky, A., Balazs, B., Szallasi, Z., Timar, J.,
Sch€afer, R., 2012. Recurrence online: an online analysis tool to
determine breast cancer recurrence and hormone receptor
status using microarray data. Breast Cancer Res. Treat. 132,
1025e1034.
Gyorffy, B., Lanczky, A., Eklund, A.C., Denkert, C., Budczies, J.,
Li, Q., Szallasi, Z., 2010. An online survival analysis tool to
rapidly assess the effect of 22,277 genes on breast cancer
prognosis using microarray data of 1,809 patients. Breast
Cancer Res. Treat. 123, 725e731.
Gyorffy, B., Molnar, B., Lage, H., Szallasi, Z., Eklund, A.C., 2009.
Evaluation of microarray preprocessing algorithms based on
concordancewithRT-PCR inclinical samples. PLoS.One4, e5645.
Gyorffy, B., Schafer, R., 2009. Meta-analysis of gene expression
profiles related to relapse-free survival in 1,079 breast cancer
patients. Breast Cancer Res. Treat. 118, 433e441.
Ha, G.H., Breuer, E.K., 2012. Mitotic kinases and p53 signaling.
Biochem. Res. Int. 2012, 195903.
Hatzis, C., Pusztai, L., Valero, V., Booser, D.J., Esserman, L.,
Lluch, A., Vidaurre, T., Holmes, F., Souchon, E., Wang, H.,
Martin, M., Cotrina, J., Gomez, H., Hubbard, R., Chacon, J.I.,
Ferrer-Lozano, J., Dyer, R., Buxton, M., Gong, Y., Wu, Y.,
Ibrahim, N., Andreopoulou, E., Ueno, N.T., Hunt, K., Yang, W.,
Nazario, A., DeMichele, A., O’Shaughnessy, J., Hortobagyi, G.N.,
Symmans, W.F., 2011. A genomic predictor of response and
survival following taxane-anthracycline chemotherapy for
invasive breast cancer. JAMA 305, 1873e1881.
Huang, D.W., Sherman, B.T., Lempicki, R.A., 2009a. Systematic
and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat. Protoc. 4, 44e57.
Huang, D.W., Sherman, B.T., Lempicki, R.A., 2009b. Bioinformatics
enrichment tools: paths toward the comprehensive functional
analysis of large gene lists. Nucleic Acids Res. 37, 1e13.
Huang, Y.F., Chang, M.D., Shieh, S.Y., 2009c. TTK/hMps1 mediates
the p53-dependent postmitotic checkpoint by
phosphorylating p53 at Thr18. Mol. Cell. Biol. 29, 2935e2944.
Iwamoto, T., Bianchini, G., Booser, D., Qi, Y., Coutant, C.,
Shiang, C.Y., Santarpia, L., Matsuoka, J., Hortobagyi, G.N.,
Symmans, W.F., Holmes, F.A., O’Shaughnessy, J.,
Hellerstedt, B., Pippen, J., Andre, F., Simon, R., Pusztai, L., 2011.
Gene pathways associated with prognosis and chemotherapy
sensitivity in molecular subtypes of breast cancer. J. Natl.
Cancer Inst. 103, 264e272.
Janssen, A., Kops, G.J., Medema, R.H., 2009. Elevating the
frequency of chromosome mis-segregation as a strategy to kill
tumor cells. Proc. Natl. Acad. Sci. U S A 106, 19108e19113.
Jemaa, M., Galluzzi, L., Kepp, O., Senovilla, L., Brands, M.,
Boemer, U., Koppitz, M., Lienau, P., Prechtl, S., Schulze, V.,
Siemeister, G., Wengner, A.M., Mumberg, D., Ziegelbauer, K.,
Abrieu, A., Castedo, M., Vitale, I., Kroemer, G., 2013.
Characterization of novel MPS1 inhibitors with preclinical
anticancer activity. Cell. Death Differ..
Jemaa, M., Vitale, I., Kepp, O., Berardinelli, F., Galluzzi, L.,
Senovilla, L., Mari~no, G., Malik, S.A., Rello-Varona, S., Lissa, D.,
Antoccia, A., Tailler, M., Schlemmer, F., Harper, F., Pierron, G.,
Castedo, M., Kroemer, G., 2012. Selective killing of p53-
deficient cancer cells by SP600125. EMBO. Mol. Med. 4,
500e514.
Jones, M.H., Huneycutt, B.J., Pearson, C.G., Zhang, C., Morgan, G.,
Shokat, K., Bloom, K., Winey, M., 2005. Chemical genetics
reveals a role for Mps1 kinase in kinetochore attachment
during mitosis. Curr. Biol. 15, 160e165.
Kanehisa, M., Goto, S., 2000. KEGG: Kyoto encyclopedia of genes
and genomes. Nucleic Acids Res. 28, 27e30.
Karn, T., Pusztai, L., Holtrich, U., Iwamoto, T., Shiang, C.Y.,
Schmidt, M., M€uller, V., Solbach, C., Gaetje, R., Hanker, L.,Ahr, A., Liedtke, C., Ruckh€aberle, E., Kaufmann, M., Rody, A.,
2011. Homogeneous datasets of triple negative breast cancers
enable the identification of novel prognostic and predictive
signatures. PLoS. One 6, e28403.
Kim, M., Wiemer, D.F., 2004. EDC-mediated condensations of 1-
chloro-5-hydrazino-9,10-anthracenedione, 1-hydrazino-9,10-
anthracenedione, and the corresponding anthrapyrazoles.
Tetrahedron Lett. 45, 4977e4980.
Leng, M., Chan, D.W., Luo, H., Zhu, C., Qin, J., Wang, Y., 2006.
MPS1-dependent mitotic BLM phosphorylation is important
for chromosome stability. Proc. Natl. Acad. Sci. U S A 103,
11485e11490.
Li, Q., Birkbak, N.J., Gyorffy, B., Szallasi, Z., Eklund, A.C., 2011.
Jetset: selecting the optimal microarray probe set to represent
a gene. BMC. Bioinfo. 12, 474.
Liu, J., Cheng, X., Zhang, Y., Li, S., Cui, H., Zhang, L., Shi, R.,
Zhao, Z., He, C., Wang, C., Zhao, H., Zhang, C., Fisk, H.A.,
Guadagno, T.M., Cui, Y., 2013. Phosphorylation of Mps1 by
BRAFV600E prevents Mps1 degradation and contributes to
chromosome instability in melanoma. Oncogene 32, 713e723.
Maire, V., Baldeyron, C., Richardson, M., Tesson, B., Vincent-
Salomon, A., Gravier, E., Marty-Prouvost, B., De Koning, L.,
Rigaill, G., Dumont, A., Gentien, D., Barillot, E., Roman-
Roman, S., Depil, S., Cruzalegui, F., Pierre, A., Tucker, G.C.,
Dubois, T., 2013. TTK/hMPS1 is an attractive therapeutic target
for triple-negative breast cancer. PLoS. One 8, e63712.
Miller, L.D., Smeds, J., George, J., Vega, V.B., Vergara, L., Ploner, A.,
Pawitan, Y., Hall, P., Klaar, S., Liu, E.T., Bergh, J., 2005. An
expression signature for p53 status in human breast cancer
predicts mutation status, transcriptional effects, and patient
survival. Proc. Natl. Acad. Sci. U S A 102, 13550e13555.
Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., 2009. Preferred
reporting items for systematic reviews andmeta-analyses: the
PRISMA Statement. Open. Med. 3, e123e130.
Murray, S., Briasoulis, E., Linardou, H., Bafaloukos, D.,
Papadimitriou, C., 2012. Taxane resistance in breast cancer:
mechanisms, predictive biomarkers and circumvention
strategies. Cancer Treat. Rev. 38, 890e903.
Neve, R.M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F.L., Fevr, T.,
Clark, L., Bayani, N., Coppe, J.P., Tong, F., Speed, T.,
Spellman, P.T., DeVries, S., Lapuk, A., Wang, N.J., Kuo, W.L.,
Stilwell, J.L., Pinkel, D., Albertson, D.G., Waldman, F.M.,
McCormick, F., Dickson, R.B., Johnson, M.D., Lippman, M.,
Ethier, S., Gazdar, A., Gray, J.W., 2006. A collection of breast
cancer cell lines for the study of functionally distinct cancer
subtypes. Cancer Cell. 10, 515e527.
Olivier, M., Langerød, A., Carrieri, P., Bergh, J., Klaar, S., Eyfjord, J.,
Theillet, C., Rodriguez, C., Lidereau, R., Bieche, I., Varley, J.,
Bignon, Y., Uhrhammer, N., Winqvist, R., Jukkola-
Vuorinen, A., Niederacher, D., Kato, S., Ishioka, C., Hainaut, P.,
Børresen-Dale, A.L., 2006. The clinical value of somatic TP53
gene mutations in 1,794 patients with breast cancer. Clin.
Cancer Res. 12, 1157e1167.
Reme, T., Hose, D., Theillet, C., Klein, B., 2013. Modeling risk
stratification in human cancer. Bioinformatics 29, 1149e1157.
Santarpia, L., Iwamoto, T., Di Leo, A., Hayashi, N., Bottai, G.,
Stampfer, M., Andre, F., Turner, N.C., Symmans, W.F.,
Hortobagyi, G.N., Pusztai, L., Bianchini, G., 2013. DNA repair
gene patterns as prognostic and predictive factors in
molecular breast cancer subtypes. Oncologist 18, 1063e1073.
Santarpia, L., Qi, Y., Stemke-Hale, K., Wang, B., Young, E.J.,
Booser, D.J., Holmes, F.A., O’Shaughnessy, J., Hellerstedt, B.,
Pippen, J., Vidaurre, T., Gomez, H., Valero, V., Hortobagyi, G.N.,
Symmans, W.F., Bottai, G., Di Leo, A., Gonzalez-Angulo, A.M.,
Pusztai, L., 2012. Mutation profiling identifies numerous rare
drug targets and distinct mutation patterns in different
clinical subtypes of breast cancers. Breast Cancer Res. Treat.
13, 333e343.
MO L E C U L A R O N C O L O G Y 8 ( 2 0 1 4 ) 5 0 8e5 1 9 519Sotiriou, C., Pusztai, L., 2009. Gene-expression signatures in
breast cancer. N. Engl. J. Med. 360, 790e800.
Sotiriou, C., Wirapati, P., Loi, S., Harris, A., Fox, S., Smeds, J.,
Nordgren, H., Farmer, P., Praz, V., Haibe-Kains, B., Desmedt, C.,
Larsimont, D., Cardoso, F., Peterse, H., Nuyten, D., Buyse, M.,
Van de Vijver, M.J., Bergh, J., Piccart, M., Delorenzi, M., 2006.
Gene expression profiling in breast cancer: understanding the
molecular basis of histologic grade to improve prognosis.
J. Natl. Cancer Inst. 98, 262e272.
Tannous, B.A., Kerami, M., Van der Stoop, P.M., Kwiatkowski, N.,
Wang, J., Zhou, W., Kessler, A.F., Lewandrowski, G.,
Hiddingh, L., Sol, N., Lagerweij, T., Wedekind, L., Niers, J.M.,
Barazas, M., Nilsson, R.J., Geerts, D., De Witt Hamer, P.C.,
Hagemann, C., Vandertop, W.P., Van Tellingen, O., Noske, D.P.,
Gray, N.S., W€urdinger, T., 2013. Effects of the selective MPS1
inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic
drugs. J. Natl. Cancer Inst. 105, 1322e1331.
Troester, M.A., Herschkowitz, J.I., Oh, D.S., He, X., Hoadley, K.A.,
Barbier, C.S., Perou, C.M., 2006. Gene expression patterns
associated with p53 status in breast cancer. BMC. Cancer 6,
276.Turner, N., Moretti, E., Siclari, O., Migliaccio, I., Santarpia, L.,
D’Incalci, M., Piccolo, S., Veronesi, A., Zambelli, A., Del Sal, G.,
Di Leo, A., 2013. Targeting triple negative breast cancer: is p53
the answer? Cancer Treat. Rev. 39, 541e550.
Walerych, D., Napoli, M., Collavin, L., Del Sal, G., 2012. The rebel
angel: mutant p53 as the driving oncogene in breast cancer.
Carcinogenesis 33, 2007e2017.
Weaver, B.A., Cleveland, D.W., 2005. Decoding the links between
mitosis, cancer, and chemotherapy: the mitotic checkpoint,
adaptation, and cell death. Cancer Cell. 8, 7e12.
Wei, J.H., Chou, Y.F., Ou, Y.H., Yeh, Y.H., Tyan, S.W., Sun, T.P.,
Shen, C.Y., Shieh, S.Y., 2005. TTK/hMps1 participates in the
regulation of DNA damage checkpoint response by
phosphorylating CHK2 on threonine 68. J. Biol. Chem. 280,
7748e7757.
Weiss, E., Winey, M., 1996. The Saccharomyces cerevisiae spindle
pole body duplication gene MPS1 is part of a mitotic
checkpoint. J. Cell. Biol. 132, 111e123.
Yerushalmi, R., Woods, R., Ravdin, P.M., Hayes, M.M.,
Gelmon, K.A., 2010. Ki67 in breast cancer: prognostic and
predictive potential. Lancet Oncol. 11, 174e183.
